Table I.
Summary of drug-provoked rupioid psoriasis (RupP) cases identified in PubMed
| Study | Drug | Age (years)/Sex | Refractory period (months)† | R/O∗ | Location | Other presenting symptoms | Psoriasis history | Type | Drug d/c | Treatment | Time to resolution (weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nascimento et al13 | Carbolithium | 38/M | 10 | O | Diss | Pain, pruritis | No | DNI | Yes | MTX (15 mg/week), urea (10%) emollient | 4 |
| Marti-Marti et al14 | Pembrolizumab | 67/M | 1.5 | R | Diss | Nail dystrophy, palmoplantar keratoderma | Yes | INLS | Yes | Acitretin (25 mg/day), SA (10%), triamcinolone acetonide (0.1%) |
NS |
| Gomez-Arias et al15 | Valproic acid | 42/M | 2.5 | R | Dorsal hands | NS | Yes | Agg | No | MTX (15 mg/week) | 8 |
| Bonciani et al16 | Prednisone | 54/F | NS | R | Diss | Fever, chills, rigors | Yes | Agg | NS | Acitretin (30 mg/day), urea (20%) ointment |
3 |
| Current case | Treprostinil, macitentan, tadalafil | 69/F | 12 | R | Diss | None | No | DNI | No | See above | 8 |
Agg, Aggravation of pre-existing lesion; d/c, discontinued; Diss, disseminated; DNI, de-novo induction; F, female; INLS, induction of non-lesional skin in patient with psoriasis history; M, male; MTX, methotrexate; NS, not specified; O, ostraceous; R, rupioid; SA, salicylic acid.
∗
Some authors consider RupP and ostraceous psoriasis synonyms and use the terms interchangeably to describe the same hyperkeratotic psoriasis variant.13
†
Time to RupP onset since drug initiation.